Form 4: Boston Scientific Director Equity Awards

Cheryl Pegus, a Director at Boston Scientific, received annual equity awards in the form of deferred stock units on May 7, 2026.

Summary

• Cheryl Pegus, a Director at Boston Scientific Corp., was granted deferred stock units (DSUs) on May 7, 2026.
• These awards represent a commitment to issue shares of Boston Scientific common stock.
• One award consists of 3,800 DSUs, granted as an annual equity award that vests upon the next annual stockholder meeting. Shares will be issued upon Pegus's separation from the Board.
• Another award consists of 1,281 DSUs, granted in lieu of 50% of her yearly cash compensation. These also vest upon the next annual stockholder meeting, with shares issued upon separation from the Board.
• The value of the first award was $215,000, and the second award was valued at $72,500, based on the closing stock price on the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to standard director compensation and does not provide new financial performance data or strategic shifts.

Positives

• Director Pegus received equity awards, aligning her interests with shareholders.
• The awards are structured as deferred stock units, indicating a long-term incentive.

Negatives

• The filing details compensation for a director, which is standard but not indicative of company performance.

Risks

• The value of the deferred stock units is subject to the future performance and stock price of Boston Scientific.
• Vesting and issuance of shares are contingent upon continued service and separation from the Board.

Future Outlook

The future outlook for the deferred stock units is tied to the company's stock performance and the director's continued service, with shares to be issued upon separation from the Board.

Industry Context

StockSavvy.ai notes that the issuance of deferred stock units to directors is a common practice in the medical technology industry to incentivize long-term commitment and align executive interests with shareholder value.

Comparison to Industry Standards

• The structure of equity awards for non-employee directors, including vesting schedules and in-lieu-of-cash compensation, is consistent with industry norms observed among companies like Medtronic, Abbott Laboratories, and Stryker.
• The use of deferred stock units is a prevalent method for retaining and compensating board members in the healthcare sector.

Stakeholder Impact

• Shareholders: The equity awards align director interests with those of shareholders, potentially promoting decisions that enhance long-term shareholder value.
• Employees: Indirect impact through director oversight and governance, which can influence company strategy and performance.
• Management: Standard compensation practice for directors, not directly impacting operational management.

Next Steps

• Shares of Boston Scientific common stock will be issued to Cheryl Pegus following her separation from Board of Director service.
• The deferred stock units vest in full upon the next annual meeting of stockholders.

Key Dates

Keywords

Boston Scientific, BSX, Form 4, Director Compensation, Equity Award, Deferred Stock Units, Cheryl Pegus, SEC Filing